炎症性肠病与原发性硬化性胆管炎对结直肠癌风险的影响:全国队列研究
基于瑞典国家患者登记库的全国队列研究,纳入1969至2014年确诊的炎症性肠病患者及每例5名匹配对照,评估原发性硬化性胆管炎(PSC)对结直肠癌风险、死亡率和结肠切除术的影响。炎症性肠病患者结直肠癌风险升高(HR 1.83,95%CI 1.72-1.96,P<.001),PSC阳性且20岁及以下确诊炎症性肠病患者风险尤为突出(IRR 74.97,95%CI 44.7-126.1,P<.001)。
要点
- 炎症性肠病患者结直肠癌风险升高,HR为1.83(95%CI 1.72-1.96,P<.001)。
- PSC阳性且20岁及以下确诊炎症性肠病患者结直肠癌风险IRR达74.97(95%CI 44.7-126.1,P<.001)。
- PSC阳性患者同步癌发生率为4.7%,PSC阴性患者为4.4%,对照组为1.9%(P<.001)。
核心结论
- 炎症性肠病患者结直肠癌风险升高,在年轻PSC阳性患者中最为突出。
- PSC阳性患者呈现近端结肠结直肠癌及更多同步癌的倾向。
- 作者认为在监测和咨询炎症性肠病患者时应考虑上述风险。
研究设计与样本
- 研究为全国队列研究,数据来自瑞典国家患者登记库。
- 纳入1969至2014年确诊的炎症性肠病患者,并按每例5名从背景人群匹配对照。
- 评估PSC±等危险因素对炎症性肠病患者结直肠癌风险、死亡率及炎症性肠病队列内结肠切除术的影响。
主要发现
- 全部炎症性肠病患者结直肠癌风险HR为1.83(95%CI 1.72-1.96,P<.001)。
- PSC阳性患者最初结直肠癌风险最高,但随时间下降。
- PSC阳性且20岁及以下确诊炎症性肠病患者与对照相比IRR为74.97(95%CI 44.7-126.1,P<.001)。
- PSC阳性患者盲肠/升结肠、横结肠、降结肠癌风险为对照散发性结直肠癌的9至16倍。
- 同步癌在PSC阳性患者中占4.7%,PSC阴性患者中占4.4%,对照组中占1.9%(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC). Previous studies concluded that primary sclerosing cholangitis (PSC) is an independent risk factor for CRC in IBD. We aimed to investigate the impact of IBD and PSC on the risk of developing CRC, mortality, and colectomy. METHODS: Patients with IBD diagnosed between 1969 and 2014 were identified from the Swedish National Patient Register, together with 5 matched controls per case from the background population. We estimated the impact of some risk factors including PSC± on the risk of CRC and mortality in the patients with IBD compared with that in the controls, and colectomy within the IBD cohort. RESULTS: Among all patients with IBD, the hazard ratio (HR) of CRC was 1.83 (95% confidence interval [CI], 1.72-1.96; P < .001). The risk was highest in the PSC+ patients initially but decreased over time. PSC+ patients diagnosed with IBD ≤20 years of age had a highly increased risk with an incidence rate ratio (IRR) of 74.97 (95% CI, 44.7-126.1; P < .001) compared with controls. PSC+ patients had 9 to 16 times higher risk of cancer in cecum/ascending, transverse, and descending colon compared with sporadic CRC among controls. Synchronous cancer was found in 4.7% of PSC+ patients, 4.4% of PSC- patients, and 1.9% among controls (P < .001). CONCLUSIONS: Patients with IBD have an increased risk of CRC, mostly prominent among young PSC+ patients. PSC+ patients display a tendency to develop CRC in the proximal colon and more synchronous CRC. This should be considered when monitoring and counseling patients with IBD.
引用
- Abdalla M, Eberhardson M, Landerholm K, et al. Impact of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis on Colorectal Cancer Risk: National Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40706734. doi:10.1016/j.cgh.2025.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。